Surprising culprit tied to 1 in 8 cancer cases worldwide, major study reveals By Melissa Rudy Fox News Published October 1, 2026 7:00am EDT (++...) +...

https://www.foxnews.com/health/surprising-culprit-tied-1-8-cancer-cases-worldwide-major-study-reveals?lid=i3pke6nuu72t Surprising culprit tied to 1 in 8 cancer cases worldwide, major study reveals 12 infections were tied to 2.3 million cancer cases in 2024, as oncologist shares prevention tips Melissa Rudy By Melissa Rudy Fox News Published October 1, 2026 7:00am EDT https://www.foxnews.com/health Lifestyle https://www.foxnews.com/lifestyle?lid=dao8o0gr8jb4

FDA approves pirtobrutinib for previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pirtobrutinib-previously-untreated-chronic-lymphocytic-leukemia-or-small-lymphocytic On October 2, 2026, the Food and Drug Administration approved pirtobrutinib (Jaypirca, Eli Lilly and Company) for adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion.

The Role of Antidiabetic Drugs in Cutaneous Malignancies: An Evidence-Based Review (++)

The Role of Antidiabetic Drugs in Cutaneous Malignancies: An Evidence-Based Review Seanna Yang, MD; Nickoulet Babaei, MD; Dahyeon Kim, MD; Mireya Cervantes, MD; Minka Gill, MD; Jashin J. Wu, MD https://www.medscape.com/viewarticle/role-antidiabetic-drugs-cutaneous-malignancies-evidence-2026a100106u?ecd=wnl_edit_tpal_etid8756480&uac=148436CN&impID=8756480 Skin cancer is one of the more prevalent malignancies in patients with type 2 diabetes, and shared risk factors may increase susceptibility to both diseases. Antidiabetic medications may have potential roles in reducing the risk for cutaneous malignancies, while emerging evidence suggests possible therapeutic applications that warrant further investigation. We reviewed the association between type 2 diabetes and skin cancer and examined the potential effects of antidiabetic medications on cutaneous malignancies. A nonsystematic literature search was conducted, with supporting articles included for additional context. Current evidence suggests that metformin and thiazolidinediones may have chemopreventive and potential therapeutic effects in skin cancers, whereas the effects of other antidiabetic medications are less well studied. Certain agents also show potential as monotherapy or adjunctive therapy to standard cancer treatments. Further research is needed to determine whether antidiabetic medications can prevent or treat skin cancer in patients with type 2 diabetes. From Convolutional Neural Networks to Foundation Models: A New Era for Artificial Intelligence in Dermatology Rhea Singh, MD; Shari R. Lipner, MD, PhD https://www.medscape.com/viewarticle/convolutional-neural-networks-foundation-models-new-era-2026a100106y?ecd=wnl_edit_tpal_etid8756480&uac=148436CN&impID=8756480 The role that artificial intelligence (AI) should play in dermatology and what it means for dermatologists have transitioned from hypothetical questions to serious clinical issues.[1,2,3,4] Consider a 36-year-old woman with Fitzpatrick skin type IV who presents to her primary care provider with a slowly enlarging pigmented lesion with features that raise the physician’s concern for malignancy. During the clinical evaluation, an AI-based image analysis tool integrated into the electronic medical record analyzes a photograph of the lesion and independently flags it as high risk, supporting the clinician’s concern. The patient then is referred to dermatology, histopathology confirms invasive melanoma, and now the patient has a diagnosis.

Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial Prof Sagar Lonial, MDa Send email to sloni01@emory.edu ∙ Prof Meletios A Dimopoulos, MDb,c ∙ Maria Gavriatopoulou, MDb ∙ Prof Kihyun Kim, MDd ∙ Prof Chang-Ki Min, MDe ∙ Albert Oriol, MDf ∙ et al.

Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial Prof Sagar Lonial, MDa Send email to sloni01@emory.edu ∙ Prof Meletios A Dimopoulos, MDb,c ∙ Maria Gavriatopoulou, MDb ∙ Prof Kihyun Kim, MDd ∙ Prof Chang-Ki Min, MDe ∙ Albert Oriol, MDf ∙ et al. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00450-X/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ims26&_hsenc=p2ANqtz--hzbEX0tUUh7eZZeRTeGq5sidbMN8haHsXcXt0bwOBrUsMk42dPY-eSMPHLiyE8mMxJPyqrv6Xd4GW6CSm8CJibJw9Qw&_hsmi=442274516&utm_source=hs_email

Reminder: explore our content from DGG 2026 (+++)

Understanding peripheral arterial disease in the current era Open Access https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00846-9/fulltext?dgcid=hubspot_email_conferencealerts_dgg26&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-9LABl5MLN-R5LAbyRCvxJHBIOFzMrcXRK40S-1KL6Fif8nVw5wO5NOfS5A7_nEiIbANMXbDn0jG2hfNzgYgAXIbh1xrQ&_hsmi=442274702&utm_source=hs_email Understanding peripheral arterial disease in the current era Prof Christian-Alexander Behrendt, MDa,b Send email to behrendt@hamburg.de ∙ Prof Lars Norgren, PhDc ∙ Chalotte W Nicolajsen, PhDd ∙ Prof Janet T Powell, PhDe,* ∙ Prof Vivienne Chuter, PhDf ∙ Prem Chand Gupta, MSg ∙ et al. Current advancements in the care of peripheral arterial disease: modern approaches to medical, endovascular, and surgical treatment Free with registration until Oct 4th, 2026 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00845-7/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_dgg26&_hsenc=p2ANqtz-8FtTc2-27U5liSgQ9Pb3rtxd6P9gCgE1SaGfzeLSRlY-8ZHSdYoyNsk-vwvmoKZfgdNASLk1Eb2vhAqwp0jEIVbetriw&_hsmi=442274702&utm_source=hs_email Current advancements in the care of peripheral arterial disease: modern approaches to medical, endovascular, and surgical treatment Riikka Tulamo, PhDa Send email to riikka.tulamo@hus.fi ∙ Prof Andrew Bradbury, FRCSb ∙ Caitlin W Hicks, MDc ∙ Prof Anders Gottsäter, PhDd ∙ Prem Chand Gupta, MSe ∙ Prof Ulrich Rother, MDf ∙ et al. Peripheral arterial disease: adverse impacts, disparities in outcomes, and the path ahead Open Access https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00847-0/fulltext?dgcid=hubspot_email_conferencealerts_dgg26&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz--B1JEW5oYB1VESfaczmEzX7IICmcVTeDK8O3zeHkXzJg_OjZEx40d_waiClJpMu9SXg2FUSYjHLGudPcubaWEl8Mf4rg&_hsmi=442274702&utm_source=hs_email Peripheral arterial disease: adverse impacts, disparities in outcomes, and the path ahead Prof Jonathan Golledge, MChira,b,c Send email to jonathan.golledge@jcu.edu.au ∙ Prof Mette Søgaard, PhDd,e ∙ Prof Mikael Svensson, PhDf ∙ Prem Chand Gupta, MSg ∙ Prof Sigrid Nikol, PhDh,i ∙ Prof Paulo Eduardo Ocke Reis, PhDj ∙ et al.

Accelerating equitable cancer genomics and precision oncology in health care and research: a Lancet Oncology Commission Raffaella Casolino, MD PhDa Send email to raffaella.casolino@glasgow.ac.uk ∙ Joaquin Mateo, MD PhDc ∙ Prof Elisabeth G E de Vries, MDd ∙ Amber Johns, BMedSci PhDa ∙ Melanie Courtot, PhDe,f,g ∙ Prof Rita T Lawlor, PhDj ∙ et al.

Accelerating equitable cancer genomics and precision oncology in health care and research: a Lancet Oncology Commission Raffaella Casolino, MD PhDa Send email to raffaella.casolino@glasgow.ac.uk ∙ Joaquin Mateo, MD PhDc ∙ Prof Elisabeth G E de Vries, MDd ∙ Amber Johns, BMedSci PhDa ∙ Melanie Courtot, PhDe,f,g ∙ Prof Rita T Lawlor, PhDj ∙ et al. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00302-5/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_wcc26&_hsenc=p2ANqtz-8Icy3oe1_nFvpREUVOnm6jrEYqE23yRz93q0vv438UInrVq8Tc-FDH7wshJAlwkLfbCRfvLzgf1nmpwNS9nfT0BFB8rA&_hsmi=442274309&utm_source=hs_email

Second Indication for Aqneursa in Ataxia Telangiectasia by Madaline Spencer| Published on: Sep 22, 2026

https://checkrare.com/second-indication-for-aqneursa-in-ataxia-telangiectasia/ The US Food and Drug Administration (FDA) has approved Aqneursa (levacetylleucine) for oral suspension to treat ataxia in patients with ataxia-telangiectasia who weigh at least 33 pounds (15 kg). It is the first treatment approved for this rare condition. Ataxia telangiectasia is a rare genetic disorder that affects the nervous system, the immune system, and many other parts of the body. The condition is typically characterized by early childhood onset of cerebellar ataxia, oculomotor apraxia, telangiectasias, choreoathetosis, a weakened immune system with frequent infections, and an increased risk of cancers such as leukemia and lymphoma. It is caused by changes in the ATM gene located on chromosome 11q22-23.